Tenascin C Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tenascin C is a large hexameric extracellular matrix glycoprotein with anti-adhesive properties. It is expressed during development and re-expressed in injury, inflammation, and cancer. In the brain, it is associated with amyloid plaques in AD.
Tenascin-C is an extracellular matrix glycoprotein expressed in the developing and adult nervous system. It modulates neuronal migration, axon guidance, synaptic plasticity, and glial scarring. Tenascin-C is upregulated in response to injury and in various neurological diseases.
This protein is involved in:
| Attribute | Value |
|---|---|
| Protein Name | Tenascin C |
| Gene | TNC |
| UniProt ID | P24821 |
| PDB Structures | 1QB0, 1Q7U, 4TPS |
| Molecular Weight | 240-320 kDa |
| Subcellular Localization | Extracellular matrix |
| Protein Family | Tenascin family |
The Tenascin C protein belongs to the Tenascin family. The protein has a characteristic structure with.
Tenascin C is involved in extracellular matrix organization and tissue remodeling.
Tenascin C plays a role in AD pathogenesis through expression around plaques and astrocyte reactivity.
Tenascin C contributes to PD through extracellular matrix remodeling in PD brain.
The protein is implicated in gliomas and fibrosis.
| Drug/Approach | Target | Status | Description |
|---|---|---|---|
| Brilliant Blue G | P2X7 | Preclinical | Antagonist, reduces neuroinflammation |
| A-438079 | P2X7 | Preclinical | Antagonist, blocks channel opening |
| Anti-C1q antibodies | C1q | Clinical | Reduce complement-mediated damage |
| CCR2 antagonists | CCL2/CCR2 | Preclinical | Block monocyte recruitment |
| Galectin-3 inhibitors | LGALS3 | Preclinical | Reduce microglial activation |
The study of Tenascin C Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Tenascin C is a large hexameric glycoprotein with a complex domain architecture:
The FNIII repeats undergo extensive alternative splicing, generating multiple isoforms with different functional properties. This plasticity allows tenascin C to regulate cell behavior in context-dependent ways.
Tenascin C shows spatiotemporally restricted expression:
Tenascin C interacts with multiple receptor systems:
Tenascin C is a DAMP (damage-associated molecular pattern) molecule:
| Approach | Target | Stage | Notes |
|---|---|---|---|
| Anti-TNC antibodies | Tenascin C | Preclinical | Blocking antibody |
| TNC-derived peptides | Integrins | Discovery | Mimetic peptides |
| Gene silencing | TNC mRNA | Preclinical | siRNA approaches |
| Small molecule inhibitors | TNC-binding | Discovery | Early stage |